Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Resectable NSCLC × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 100 Breast Neoplasms 92 Prostatic Neoplasms 67 Multiple Myeloma 60 Neoplasms 56 Neoplasm Metastasis 52 Leukemia, Myeloid, Acute 49 Colorectal Neoplasms 49 Lung Neoplasms 48 Squamous Cell Carcinoma of Head and Neck 44 Carcinoma, Hepatocellular 37 Melanoma 36 Ovarian Neoplasms 35 Lymphoma 34 Triple Negative Breast Neoplasms 30 Carcinoma, Renal Cell 29 Brain Neoplasms 29 Sarcoma 28 Glioma 28 Lymphoma, Large B-Cell, Diffuse 27 Leukemia, Lymphocytic, Chronic, B-Cell 27 Stomach Neoplasms 26 Recurrence 26 Pancreatic Neoplasms 26 Endometrial Neoplasms 26 Hematologic Neoplasms 25 Lymphoma, Non-Hodgkin 24 Head and Neck Neoplasms 24 Urinary Bladder Neoplasms 23 Precursor Cell Lymphoblastic Leukemia-Lymphoma 23

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡